drugset / Trial / NCT05857982
Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1/2
Unknown
20 enrolled
Second Affiliated Hospital of Soochow University
The Affiliated Hospital of Xuzhou Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
A prospective, open-label, single-arm clinical study of mitoxantrone hydrochloride liposome injection combined with daratumumab and dexamethasone in the treatment of relapsed/refractory multiple myeloma
Timeline
- Start
- 2023-05-20
- Primary completion
- 2025-01-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 16 mg/kg | — |
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Mitoxantrone | Small molecule | 20 mg/m2 | — |